Achieving sufficient delivery across the blood–brain barrier is a key challenge in the
development of drugs to treat central nervous system (CNS) disorders. This is particularly …

Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug
development remains challenging, with high costs, long pathways to clinical use and high …

The blood-brain barrier (BBB) constitutes a microvascular network responsible for excluding
most drugs from the brain. Treatment of brain tumors is limited by the impermeability of the …

The restrictive nature of the blood–brain barrier (BBB) creates a major challenge for brain
drug delivery with current nanomedicines lacking the ability to cross the BBB. Extracellular …

Protein-based therapeutics are an attractive alternative to established therapeutic
approaches and represent one of the fastest growing families of drugs. While many of these …

Nanomaterial-based drug delivery systems (NBDDS) are widely used to improve the safety
and therapeutic efficacy of encapsulated drugs due to their unique physicochemical and …

Obtaining efficient drug delivery to the brain remains the biggest challenge for the
development of therapeutics to treat diseases of the central nervous system. The main …

The lack of safe and effective delivery across the blood-brain barrier and the profound
immune suppressive microenvironment are two main hurdles to glioblastoma (GBM) …

Lipid nanoparticles (LNPs) have revolutionized the field of drug delivery through their
applications in siRNA delivery to the liver (Onpattro) and their use in the Pfizer-BioNTech …

Ischemic cerebral stroke is a major cause of death and morbidity. Currently, no
neuroprotective agents have been shown to impact the clinical outcomes in cerebral stroke …